Drexel University

Rutgers, the State University of New Jersey

University of Washington

Albert Einstein College of Medicine

University of Medicine and Dentistry of New Jersey

Mmv Medicines for Malaria Venture

Palacky University Olomouc

Sandhya Kortagere

Joseph M Salvino

Andreia C K Mortensen

Eldo V Kuzhikandahil

Ole Valente Mortensen

Akhil Vaidya

Carol M Artlett

Matthew J Wyvratt

Arnab Kumar Chatterjee

Advait Suresh Nagle

William J Welsh

Sridhar Mani

Erkang Fan

Lawrence W Bergman

Felix Kopp

Jeremy Burrows

Chamini Karunaratne

Zdenek Dvorak

Tomoyo Kato

The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.

Glutamate transporter activators and methods using same

The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention.

Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder

Small molecule agonists of the pregnane X receptor (PXR), compositions and methods are disclosed for treating or preventing gut barrier dysfunction, an illness associated with gut barrier dysfunction, toxic or inflammatory injury to intestines, or leaky intestinal (gut) syndrome in a subject.

PXR agonists and uses thereof for gut barrier dysfunction treatment and prevention

The present invention provides compounds useful for treating or preventing an IL-1R-mediated disease or disorder. In certain embodiments, the disease or disorder comprises scleroderma.

Compounds and methods of treating or ameliorating an IL-1R-mediated disease or disorder using same

The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.

D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease

The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. 

Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder

Ddopamine receptor agonists to treat dyskinesia in Parkinson's disease

The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter.

Compositions useful in treating brain-related diseases or disorders and methods using same

D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease

The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, the method comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter.

The present invention is related to a use of pyrazole derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to pyrazole derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

Anti-malarial agents

[object Object]

Growing community of inventors

Newtown, PA, United States of America

Sandhya Kortagere